Please login to the form below
urothelial carcinoma
This page shows the latest urothelial carcinoma news and features for those working in and with pharma, biotech and healthcare.
Seattle Genetics makes case for Padcev plus Keytruda in first-line bladder cancer
At the tail-end of last year, Seattle and Astellas scored US approval for Padcev (enfortumab vedotin) for the treatment of locally-advanced or metastatic urothelial carcinoma – the most common form ... The initial results from the phase 1b/2 EV-103
Latest news
-
Keytruda claims first place in bladder cancer race
covers patients with early-stage high grade cancer cells – carcinoma-in-situ (CIS) – with or without papillary tumours. ... Keytruda has already been approved for first- and second-line treatment of urothelial carcinoma, another form of bladder
-
Merck KGaA, Pfizer’s Bavencio improves survival in bladder cancer
In May 2017, Bavencio (avelumab) claimed approval as a second-line treatment in patients with locally advanced or metastatic urothelial carcinoma (UC) whose disease progressed during or following platinum-containing chemotherapy. ... Our unique
-
J&J taps TARIS Biomedical for novel bladder cancer technology
Merck’s blockbuster checkpoint inhibitor Keytruda (pembrolizumab) is also approved for first- and second-line treatment of urothelial carcinoma, the most common form of bladder cancer.
-
Seattle, Astellas bag speedy FDA okay for bladder cancer drug
Padcev (enfortumab vedotin) is indicated for the treatment of locally-advanced or metastatic urothelial carcinoma – the most common form of bladder cancer – in adults who have previously been treated with chemotherapy ... Keytruda has already been
-
FDA panel clears Keytruda for hard-to-treat bladder cancer
Keytruda was filed for approval on the strength of the single-arm, phase 2 KEYNOTE-057 trial of the PD-1 inhibitor in 102 high-risk NMIBC patients, who had carcinoma ... Keytruda has already been approved for first- and second-line treatment of
More from news
Approximately 3 fully matching, plus 32 partially matching documents found.
Latest Intelligence
-
Europe vs the US: New drug product approvals
Tecentriq (for the treatment of urothelial carcinoma, only approved in the US), and Venclexta (for the treatment of chronic lymphocytic leukaemia, approved in the EU and US).
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Regeneron says antibody for COVID-19 could be ready this year
- Amgen adds Otezla to the COVID-19 candidate list
- UK clears NHS use of Gilead’s remdesivir for COVID-19 patients
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- NICE approves Roche’s Tecentriq in TNBC after revising deal
- CEPI-backed coronavirus vaccine from Novavax starts trials
- IFPMA industry association conference: ‘no-one left behind’ on coronavirus vaccine
- Roche/Gilead tag team fights COVID-19 with Actemra/remdesivir
- GSK plans to produces one billion doses of vaccine adjuvant for COVID-19
- The big issue
- The field team are off the road! What should they do next?
- INFOGRAPHIC 02: The Importance of clinical study websites
PMHub
JPA Health
JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...
Latest intelligence
- The big issue
- Whether you want to lead or follow, you need to understand the elephant in the C-suite...
- INFOGRAPHIC 02: The Importance of clinical study websites
- Here’s a infographic of why clinical study websites are important to patient recruitment and retention strategies…...
- Working with, Advocating for, and Empowering Patients
- A holistic view of how to work with patients virtually...
Quick links
Infographics
